PUBLIC COMPANY
save$ANIPANI PHARMACEUTICALS INC
$ANIP77.32-0.90%Princeton, NJ, USupdated 4h ago
community read0 votes
pipeline
7
marketed
7
phase 3
0
catalysts ytd
5
approvals ytd
2
recalls ytd
0
Pipeline(7)
pipeline depth7 products
7Marketed
Marketed
Chewtadzy
Storage Symptoms of Benign Prostatic Hyperplasia
MarketedCortenema
Proctitis
MarketedREGLAN
Diabetic Gastroparesis
Marketedfluvoxamine maleate
Obsessive-Compulsive Disorder
Marketedlithium carbonate ER
Bipolar Disorder (Manic Depression)
Marketedsinecatechins
Genital Warts (Condylomata Acuminata)
Marketedvancocin hydrochloride
Enterocolitis
Upcoming
Recent(90d)
earnings (1)
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 13, 26SELLCook Meredith· SR. VP, GENERAL COUNSEL & SEC.−$39K↗
- Mar 13, 26SELLMutz Christopher· HEAD OF RARE DISEASE−$227K↗
- Mar 13, 26SELLCook Meredith· SR. VP, GENERAL COUNSEL & SEC.−$36K↗
- Mar 11, 26SELLRowland Thomas Andrew· SVP, HEAD - ESTABLISHED BRANDS−$357K↗
- Mar 9, 26SELLDavis Krista· SVP, CHIEF HR OFFICER−$377K↗
- Mar 9, 26SELLMutz Christopher· HEAD OF RARE DISEASE−$267K↗
- Mar 6, 26SELLMutz Christopher· HEAD OF RARE DISEASE−$157K↗
- Mar 6, 26SELLDavis Krista· SVP, CHIEF HR OFFICER−$111K↗
- Mar 5, 26SELLCAREY STEPHEN P.· SVP & CFO−$302K↗
- Mar 5, 26SELLCAREY STEPHEN P.· SVP & CFO−$250K↗
- Mar 3, 26SELLWalsh Patrick D· −$445K↗
- Mar 3, 26SELLGutwerg Ori· SVP, GENERICS−$158K↗
- Mar 2, 26SELLMutz Christopher· HEAD OF RARE DISEASE−$31K↗
routine RSU / option mechanics (6)
- Mar 7, 26tax coverLalwani Nikhil · PRESIDENT & CEO17,060 sh
- Mar 7, 26tax coverCAREY STEPHEN P. · SVP & CFO5,150 sh
- Mar 7, 26tax coverMutz Christopher · HEAD OF RARE DISEASE3,314 sh
- Mar 7, 26tax coverGutwerg Ori · SVP, GENERICS3,314 sh
- Mar 5, 26option exerciseCAREY STEPHEN P. · SVP & CFO3,312 sh
- Mar 5, 26option exerciseCAREY STEPHEN P. · SVP & CFO3,312 sh
🐶 Hiring Signal
next earnings Nov 6, 2026
News
- Trump threatens tariffs on imported generic drugsWhile the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to 200% on copycat medicines could — depending on the specifics — prove mor…biopharma_dive · 29d ago
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that